A law in the European community that requires companies to sell new stock to existing customers is hampering the move from R&D to product development for many bioscience companies, according to Scotsman.com News. “Bioscience companies should be able to issue up to 20% of new shares in any three-year period without pre-emption rights applying.”

Fresh money and fresh ideas. Makes sense that you’d need those to move ahead. Does U.S. law contain any such restrictive provisions? Will look into that. Forging into product development is hard enough already…